Related Experiment Videos
Simplified Reverse Dot Blot Analyses for Detecting of ras Oncogene Mutations
1Section of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Molecular Diagnosis : a Journal Devoted to the Understanding of Human Disease Through the Clinical Application of Molecular Biology
|August 27, 1999
Summary
The simplified reverse dot blot (RDB) assay reliably detects ras gene mutations, outperforming single-strand conformation polymorphism (SSCP) assays. This sensitive method aids in identifying minimal residual disease, especially in leukemia.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Ras gene family mutations (H-ras, K-ras, N-ras) are prevalent in human cancers.
- Accurate detection of these mutations is crucial for diagnosis and treatment.
- Existing methods for ras mutation detection have limitations.
Purpose of the Study:
- To evaluate a simplified reverse dot blot (RDB) assay for detecting ras gene mutations.
- To compare the reliability and sensitivity of the RDB assay against the single-strand conformation polymorphism (SSCP) assay.
Main Methods:
- Utilized a simplified reverse dot blot (RDB) assay with polymerase chain reaction (PCR) products hybridized to specific probes.
- Tested probes for codons 12, 13, and 61 of H-, K-, and N-ras mutations and wild-type sequences.
- Assessed RDB assay performance using both radioactive ((32)P) and chemiluminescent detection systems.
Main Results:
- The RDB assay demonstrated high sensitivity, detecting mutations when the mutant allele comprised only 1% of cells.
- Compared to SSCP, the RDB assay proved significantly more reliable, sensitive, and specific, with no false positives or negatives.
- SSCP assays showed a 12% false positive rate and a 2% false negative rate when validated by sequencing.
Conclusions:
- The simplified RDB assay is a highly sensitive and accurate method for detecting ras gene mutations.
- This assay provides detailed information on specific point mutations and amino acid changes, potentially aiding clinical decision-making.
- The RDB assay's sensitivity makes it suitable for detecting minimal residual disease, particularly in leukemia and myelodysplasia.